These findings provide novel insights into the use of RIPK2 as a biomarker for Taxol resistance and its possible mechanisms, paving the way for a possible solution to Taxol resistance in serous ovarian cancer. Here, RIPK2 is linked to ovarian serous adenocarcinoma.